Automated behavioral phenotyping reveals presymptomatic alterations in a SCA3 genetrap mouse model.

[1]  L. Rüttiger,et al.  Nuclear Localization of Ataxin-3 Is Required for the Manifestation of Symptoms in SCA3: In Vivo Evidence , 2007, The Journal of Neuroscience.

[2]  L. Packer,et al.  The threshold of age in exercise and antioxidants action. , 1992, EXS.

[3]  Andreas Wenzel,et al.  In vivo confocal imaging of the retina in animal models using scanning laser ophthalmoscopy , 2005, Vision Research.

[4]  M. Rep,et al.  Macrophages in T and B Cell Compartments and Other Tissue Macrophages Recognized by Monoclonal Antibody MOMA‐2 , 1987, Scandinavian journal of immunology.

[5]  J. Crawley.  Behavioral phenotyping of rodents. , 2003, Comparative medicine.

[6]  H. Arnold,et al.  N-terminal ataxin-3 causes neurological symptoms with inclusions, endoplasmic reticulum stress and ribosomal dislocation. , 2011, Brain : a journal of neurology.

[7]  Olaf Riess,et al.  Neurobehavioral tests in rat models of degenerative brain diseases. , 2010, Methods in molecular biology.

[8]  T. Steckler,et al.  The fallacy of behavioral phenotyping without standardisation , 2002, Genes, brain, and behavior.

[9]  F. Alt,et al.  Structure and expression of the human and mouse T4 genes. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[10]  B. Dubois,et al.  Riluzole in Huntington's disease: a 3‐year, randomized controlled study , 2007, Annals of neurology.

[11]  J. Schiefer,et al.  Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[12]  H. C. van der Heyde,et al.  Gamma delta T cells function in cell-mediated immunity to acute blood-stage Plasmodium chabaudi adami malaria. , 1995, Journal of immunology.

[13]  B. Winblad,et al.  The Cerebrocortical Areas in Normal Brain Aging and in Alzheimer's Disease: Noticeable Differences in the Lipid Peroxidation Level and in Antioxidant Defense , 2001, Neurochemical Research.

[14]  Andrew D. Steele,et al.  The power of automated high-resolution behavior analysis revealed by its application to mouse models of Huntington's and prion diseases , 2007, Proceedings of the National Academy of Sciences.

[15]  Ole A. Andreassen,et al.  Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington's Disease , 2002, The Journal of Neuroscience.

[16]  Serum levels of a subset of cytokines show high interindividual variability and are not altered in rats transgenic for Huntington´s disease , 2010, PLoS currents.

[17]  S. Arndt,et al.  Methods for the behavioural phenotyping of mouse mutants. How to keep the overview , 2001, Behavioural Brain Research.

[18]  B. Brew,et al.  Tryptophan, Neurodegeneration and HIV-Associated Neurocognitive Disorder , 2010, International journal of tryptophan research : IJTR.

[19]  C. Wannmacher,et al.  Creatine and pyruvate prevent behavioral and oxidative stress alterations caused by hypertryptophanemia in rats , 2012, Molecular and Cellular Biochemistry.

[20]  G. Koo,et al.  Establishment of monoclonal anti-Nk-1.1 antibody. , 1984, Hybridoma.

[21]  R. Hardy,et al.  Self‐renewal of B‐1 lymphocytes is dependent on CD19 , 1996, European journal of immunology.

[22]  T. Klockgether,et al.  Inflammatory Genes Are Upregulated in Expanded Ataxin-3-Expressing Cell Lines and Spinocerebellar Ataxia Type 3 Brains , 2001, The Journal of Neuroscience.

[23]  P Chambon,et al.  EMPReSS: standardized phenotype screens for functional annotation of the mouse genome , 2005, Nature Genetics.

[24]  Steve D. M. Brown,et al.  High-throughput mouse phenotyping. , 2011, Methods.

[25]  S. Ratnofsky,et al.  The biologic roles of CD2, CD4, and CD8 in T-cell activation. , 1989, Annual review of immunology.

[26]  M. Hayden,et al.  Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. , 2012, Human molecular genetics.

[27]  P. Marrack,et al.  Characterization of a monoclonal antibody which detects all murine alpha beta T cell receptors. , 1989, Journal of immunology.

[28]  H. Waldmann,et al.  Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo , 1984, Nature.

[29]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[30]  J. Borst,et al.  Novel mAbs reveal potent co-stimulatory activity of murine CD27. , 1995, International immunology.

[31]  S. Gordon,et al.  Polymorphic expression of a neutrophil differentiation antigen revealed by monoclonal antibody 7/4 , 2004, Immunogenetics.

[32]  D. Fuchs,et al.  Degradation of tryptophan in neurodegenerative disorders. , 1999, Advances in experimental medicine and biology.

[33]  John M. Hancock,et al.  BIOINFORMATICS APPLICATIONS NOTE Databases and ontologies EMPReSS: European Mouse Phenotyping Resource for Standardized Screens , 2005 .

[34]  M. Hayden,et al.  A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease , 2008, The Journal of experimental medicine.

[35]  Annalisa Pastore,et al.  SCA3: Neurological features, pathogenesis and animal models , 2008, The Cerebellum.

[36]  J. Labandeira-Garcia,et al.  Effect of iron and manganese on hydroxyl radical production by 6-hydroxydopamine: mediation of antioxidants. , 2001, Free radical biology & medicine.

[37]  D. Borchelt,et al.  Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model , 2001, Neuroscience Letters.